Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

NCT06908694 on ClinicalTrials.gov · last registry update 2026-09-14

A small phase 4 — 20 participants, against a typical 75. Due to report 31 October 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Number of Serious Adverse Events. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 2 times since then.

Status: ACTIVE_NOT_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Hamilton Health Sciences Corporation
Sponsor type: Other
Enrollment: 20
Started: 2025-07-02
Primary completion: 2027-10-31 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-09-14	Reporting date moved	2026-07-31 → 2027-10-31 15 months later
2026-09-14	Status changed	RECRUITING → ACTIVE_NOT_RECRUITING

Primary outcome

Number of Serious Adverse Events

Conditions studied

Prostate Cancer

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.